Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Total Liabilities (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Total Liabilities readings, the most recent being $35.0 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 64.68% to $35.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $35.0 million, a 64.68% decrease, with the full-year FY2025 number at $35.0 million, down 64.68% from a year prior.
  • Total Liabilities hit $35.0 million in Q4 2025 for Aligos Therapeutics, down from $37.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $99.1 million in Q4 2024 to a low of $31.0 million in Q3 2023.
  • Median Total Liabilities over the past 5 years was $41.8 million (2022), compared with a mean of $45.9 million.
  • Biggest five-year swings in Total Liabilities: surged 84.13% in 2024 and later plummeted 64.68% in 2025.
  • Aligos Therapeutics' Total Liabilities stood at $50.6 million in 2021, then fell by 15.49% to $42.8 million in 2022, then skyrocketed by 38.92% to $59.4 million in 2023, then soared by 66.65% to $99.1 million in 2024, then tumbled by 64.68% to $35.0 million in 2025.
  • The last three reported values for Total Liabilities were $35.0 million (Q4 2025), $37.9 million (Q3 2025), and $32.8 million (Q2 2025) per Business Quant data.